Hypothesis

Intermittent dosing of dasatinib plus quercetin (D+Q) improves brain function in aging not by selectively removing inefficient neurons but by transiently restoring the lysosomal and phagocytic competence of senescent microglia, thereby enabling endogenous clearance of debris and apoptotic cells.

Mechanistic Rationale

• Dasatinib crosses the blood‑brain barrier and inhibits SRC family kinases that are hyperactive in senescent microglia, leading to a rapid decline in SASP factors such as IL‑1β and TNFα within hours of dosing.
• This kinase inhibition triggers activation of the transcription factor TFEB, a master regulator of lysosomal biogenesis, which up‑regulates LAMP1, cathepsin D, and V‑ATPase subunits in microglia.
• Quercetin, while limited in CNS penetration, reduces peripheral oxidative stress and circulating cytokine levels, lowering the inflammatory milieu that sustains microglial senescence.
• The combined effect is a short‑lived window (≈24–48 h) where microglia shift from a senescence‑associated, phagocytosis‑deficient state to a rejuvenated, debris‑clearing phenotype.
• Neuronal loss in aged brains therefore reflects insufficient clearance due to microglial senescence, not an active pruning program.

Testable Predictions

1. Lysosomal markers rise transiently in microglia isolated from aged mice 6 h after a D+Q pulse, returning to baseline by 48 h.
2. Phagocytic uptake of fluorescently labeled synapses or apoptotic neurons is significantly enhanced in microglia from D+Q‑treated aged mice compared with vehicle controls, an effect blocked by chloroquine (lysosomal inhibitor) or TFEB siRNA.
3. Cognitive benefits of intermittent D+Q (e.g., improved Morris water maze performance) are abrogated when lysosomal function is pharmacologically inhibited during the dosing window.
4. Neuronal metabolic efficiency (ATP production per unit oxygen consumption) does not increase following D+Q treatment; instead, reduced debris load correlates with lower neuronal stress markers (e.g., γH2AX, 4‑HNE).
5. Peripheral inflammation markers (serum IL‑6, CRP) decline after each D+Q cycle, correlating with the magnitude of microglial lysosomal activation.

Experimental Design

• Subjects: 20‑month‑old C57BL/6J mice, split into four groups (vehicle, continuous D+Q, intermittent D+Q, intermittent D+Q + chloroquine).
• Dosing: Dasatinib (5 mg/kg) + quercetin (50 mg/kg) i.p. for 2 consecutive days every 3 weeks (intermittent) or weekly (continuous) for 3 months.
• Readouts:
  • Flow cytometry of CD11b⁺ microglia for LAMP1, cathepsin D, p‑SRC, and SASP cytokines.
  • Ex vivo phagocytosis assay using pHrodo‑labeled synaptosomes.
  • Lysosomal activity measured by Magic Red cathepsin assay.
  • Behavioral testing (novel object recognition, spatial memory) at end of treatment.
  • Neuronal stress immunostaining and Seahorse analysis of ATP-linked respiration in synaptosome preparations.
  • Serum cytokine panels.
• Analysis: Two‑way ANOVA with post‑hoc Tukey; significance set at p < 0.05.

Potential Implications

If validated, this hypothesis reframes senolytics as modulators of glial quality‑control rather than agents that sculpt neuronal networks. It suggests that optimizing the timing and duration of D+Q pulses to match microglial lysosomal recovery cycles could maximize therapeutic benefit while minimizing off‑target toxicity. Furthermore, it opens avenues to combine senolytics with lysosomal enhancers (e.g., TFEB activators) or perif­eral anti‑inflammatory agents to amplify the restorative window without increasing drug exposure.